Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)

Completed · Phase 2 · Has a placebo group

Conditions studied: Primary Sclerosing Cholangitis (PSC)

In brief

The purpose of this study is to evaluate whether simtuzumab (GS-6624) is effective at preventing the progression of liver fibrosis in adults with primary sclerosing cholangitis (PSC).

Key facts

Study ID
NCT01672853
Run by
Gilead Sciences
People needed
235
Starts
2013-03-04
Expected to finish
2016-08-24
Last updated by the study team
2019-10-22

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.